Advanced Thermotherapy for NMIBC and Bladder Cancer Chemotherapy with COMBAT BRS

Table of Contents

• Introduction
• Understanding NMIBC
• What is the COMBAT BRS System?
• How COMBAT BRS Enhances Thermotherapy
• Clinical Benefits and Outcomes
• Scientific Evidence and Trials
• Comparison with Traditional Therapies
• Usage Across Switzerland and the EU
• Conclusion

Introduction

Bladder cancer, particularly Non-Muscle Invasive Bladder Cancer (NMIBC), poses a major challenge in urological oncology. While traditional chemotherapy has been used for decades, innovative approaches such as thermotherapy for NMIBC are gaining traction. One of the most advanced solutions in this field is the COMBAT BRS system, which combines chemotherapy with controlled hyperthermia to improve outcomes for patients with bladder cancer.

Understanding NMIBC

NMIBC affects the inner lining of the bladder without invading the muscle wall. It accounts for approximately 75% of bladder cancer cases at initial diagnosis. Standard treatment involves transurethral resection of bladder tumors (TURBT), followed by intravesical therapy. However, recurrence and progression rates remain high, necessitating more effective therapeutic options like bladder cancer chemotherapy integrated with thermotherapy.

What is the COMBAT BRS System?

The COMBAT BRS (Bladder Recirculation System) is a CE-certified device designed for hyperthermic intravesical chemotherapy (HIVEC®). It maintains a controlled temperature of 43°C to optimize mitomycin-C (MMC) delivery into the bladder wall. The system includes a recirculation unit, disposable set, and integrated safety mechanisms to ensure patient comfort and efficient drug diffusion.

How COMBAT BRS Enhances Thermotherapy

Hyperthermia improves drug absorption and cytotoxicity. The COMBAT BRS system allows consistent heating and circulation of chemotherapy agents in the bladder, thereby maximizing cancer cell eradication while minimizing systemic exposure. Patients typically undergo six weekly instillations, each lasting 60 minutes.

Clinical Benefits and Outcomes

• Reduces recurrence rates by up to 50%
• Improves disease-free survival
• Offers an effective alternative for patients unsuitable for BCG therapy
• Minimizes hospitalization due to its outpatient applicability

Scientific Evidence and Trials

Several peer-reviewed studies support the effectiveness of thermotherapy in NMIBC when used with COMBAT BRS. A 2022 multicenter trial across Europe demonstrated significantly higher recurrence-free survival at 24 months compared to standard MMC alone.

Comparison with Traditional Therapies

While BCG therapy has been a mainstay, its shortages and side effects have led to increased interest in COMBAT BRS. Thermochemotherapy offers a compelling option for intermediate- and high-risk NMIBC patients.

Usage Across Switzerland and the EU

The COMBAT BRS system is widely adopted in Switzerland, Germany, France, and Italy. It is integrated into leading urology clinics and university hospitals. Its CE certification and strong clinical backing make it ideal for widespread European deployment.

Conclusion

With its scientifically proven efficacy, ease of use, and improved patient outcomes, the COMBAT BRS system is redefining the future of bladder cancer chemotherapy and thermotherapy for NMIBC. For more details, visit the official Innomedicus COMBAT BRS page.